Analyst Ratings For ADMA Biologics Inc (NASDAQ:ADMA)
Today, HC Wainwright reiterated its Buy rating on ADMA Biologics Inc (NASDAQ:ADMA) with a price target of $10.00.
There are 6 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on ADMA Biologics Inc (NASDAQ:ADMA) is Buy with a consensus target price of $10.4167 per share, a potential 160.42% upside.
Some recent analyst ratings include
- 2/21/2019-ADMA Biologics Inc (NASDAQ:ADMA) had its Buy rating reiterated by HC Wainwright with a $10.00 price target
- 10/12/2018-ADMA Biologics Inc (NASDAQ:ADMA) had its Buy rating reiterated by Raymond James with a $10.00 price target
- 7/30/2018-ADMA Biologics Inc (NASDAQ:ADMA) has coverage initiated with a Buy rating and $10.00 price target
About ADMA Biologics Inc (NASDAQ:ADMA)
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease. The company also operates source plasma collection facilities in Norcross and Marietta, Georgia. In Addition, the company offers Nabi-HB for the treatment of acute exposure; and Bivigam for the treatment of primary humoral immunodeficiency. It distributes its products through independent distributors, sales agents, specialty pharmacies, and others. The ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.
Recent Trading Activity for ADMA Biologics Inc (NASDAQ:ADMA)
Shares of ADMA Biologics Inc closed the previous trading session at 4,00 −0,0050 0,12 % with 4.13 shares trading hands.
